ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules GlobeNewswire July 22, 2025 CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer's disease (AD), amyotrophic […]

Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma GlobeNewswire July 22, 2025 WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug

SINTX Technologies Submits FDA 510(k) for Silicon Nitride Foot & Ankle Medical Devices GlobeNewswire July 22, 2025 Advanced Material Science Meets Surgical Precision in Groundbreaking New Platform in Reconstructive Foot & Ankle Surgery Market SALT LAKE CITY, Utah, July 22, 2025 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced

Seres Therapeutics Announces Leadership Transition GlobeNewswire July 22, 2025 Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure additional capital and

Quantum BioPharma Makes Strategic Investment in GameStop Corp. GlobeNewswire July 22, 2025 TORONTO, July 22, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company“), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announced the purchase of 2,000 shares of GameStop Corp.

OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US Excellent safety observed across initial dose escalation with objective response at the lowest dose tested (1 mg/kg of AI-081) GlobeNewswire July 22, 2025 ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) —

Ready Capital Secures Ownership of The Ritz-Carlton Portland Project GlobeNewswire July 22, 2025 NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) — Ready Capital Corporation (NYSE: RC) (with its affiliates, “Ready Capital” or the “Company”), a multi-strategy real estate finance company that originates, acquires, finances, and services investor and owner-occupied commercial real estate loans, today announced

S8 Global Fintech & Regtech Fund (Luxembourg), Strategic Fintech Investor, Reports More Than 10% Ownership Position in RYVYL GlobeNewswire July 22, 2025 SAN DIEGO, CA, July 22, 2025 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), a leading innovator of payment transaction solutions, that recently announced pivoting into strategies that may include

Enthusiast Gaming's U.GG Launches Support for Rematch, Surpasses 100,000 Player Profiles in First Two Weeks GlobeNewswire July 22, 2025 TORONTO, July 22, 2025 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a digital publisher focused on building tools, platforms, and experiences for gamers, is pleased to announce that U.GG,

HydroGraph Confirms No Undisclosed Material Information or Change in Operations GlobeNewswire July 22, 2025 VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — At the request of CIRO, HydroGraph Clean Power Inc. (CSE: ‎HG) (OTCQB: HGRAF) (“HydroGraph” or the “Company”) wishes to confirm that there is no undisclosed material information at this time. The Company's